EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy

Pengjie Ji, Qiongjiao Lu, Xiaoqiang Chen, Yuebing Chen, Xiane Peng, Zhiwei Chen, Cheng Lin, Shaojun Lin, Jingfeng Zong

Cancer Research and Treatment · 2023

DOI: 10.4143/crt.2022.1651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2023. Verfasst von Pengjie Ji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian, China. Hauptthemen laut MEDLINE: Radiotherapy, Intensity-Modulated, Carcinoma, Epstein-Barr Virus Infections, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This retrospective study aimed to re-evaluate the effect of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT).Materials and Methods A total of 498 patients who received neoadjuvant chemotherapy (NCT) combined with concurrent chemoradiotherapy (CCRT) or IMRT were retrospectively reviewed. The distribution of baseline characteristics was balanced using propensity score matching. Additionally, the results of NCT+IMRT and NCT+CCRT were compared using Kaplan-Meier survival analysis, and differences in survival rates were analyzed using the log rank test.

Results

There were no significant differences in overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and local progression-free survival (LRFS) between the two groups. Patients were further categorized into risk subgroups based on pretreatment Epstein-Barr virus (EBV) DNA cutoff values using receiver operating characteristic curve analysis. There were no statistically significant differences in OS, PFS, DMFS, and LRFS between patients who received NCT+CCRT and NCT+IMRT in the high-risk group. In the low-risk group, although there were no differences between NCT+CCRT and NCT+IMRT in OS, PFS, and LRFS, patients who received NCT+CCRT had better DMFS than those who received NCT+IMRT.

Conclusion

Pretreatment EBV DNA level can be used to individualize concurrent chemotherapy for patients with locally advanced NPC. Patients with low pretreatment EBV DNA levels may benefit from concurrent chemotherapy, whereas those with high levels may not. Other treatment modalities need to be explored for high-risk patients to improve their prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiotherapy, Intensity-ModulatedCarcinomaEpstein-Barr Virus InfectionsNasopharyngeal NeoplasmsHumansNasopharyngeal CarcinomaRetrospective StudiesNeoadjuvant TherapyHerpesvirus 4, HumanChemoradiotherapyDNA

Stichwörter der Autor:innen

ChemoradiotherapyEpstein-Barr virus DNAIndividualized treatmentNasopharyngeal carcinoma

Substanzen

DNA

Autor:innen und Institutionen

  • Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian, China.
  • Department of Otolaryngology, Fujian Medical University Union Hospital, Fujian, China.
  • Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian, China.
  • Department of Preventive Medicine, School of Public Health, Fujian Medical University, Fujian, China.
  • Fuzhou Center for Disease Control and Prevention, Fuzhou, Fujian, China.
  • Fujian Key Laboratory of Translational Cancer Medicine, Fujian, China.

Zitieren

APA

Ji, P., Lu, Q., Chen, X., Chen, Y., Peng, X., Chen, Z., Lin, C., Lin, S., & Zong, J. (2023). Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy. Cancer Research and Treatment. https://doi.org/10.4143/crt.2022.1651

Vancouver

Ji P, Lu Q, Chen X, Chen Y, Peng X, Chen Z, et al. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy. Cancer Research and Treatment. 2023. doi:10.4143/crt.2022.1651

BibTeX
@article{Ji2023,
  author = {Ji, Pengjie and Lu, Qiongjiao and Chen, Xiaoqiang and Chen, Yuebing and Peng, Xiane and Chen, Zhiwei and Lin, Cheng and Lin, Shaojun and Zong, Jingfeng},
  title = {Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy},
  journal = {Cancer Research and Treatment},
  year = {2023},
  doi = {10.4143/crt.2022.1651}
}
Kostenlos starten →